Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label StudyShun Lü, Shucai Zhang, Dongqing Lv et al.|Journal of Thoracic Oncology|2022Cited by 25
Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS studyQing Zhou, Yi‐Long Wu, Helong Zhang et al.|Journal of Cancer Research and Clinical Oncology|2023Cited by 9
Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in ChinaYunpeng Yang, Li Zhang, Nong Yang et al.|Chinese Clinical Oncology|2020Cited by 8
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancerShun Lü, Yibin Wang, Yongfeng Yu et al.|Translational Lung Cancer Research|2025Cited by 2